Bristol Myers Squibb immunotherapy-chemo combination gets NICE recommendation
Treatment involves adults with certain forms of advanced stomach and oesophageal cancer
Read Moreby John Pinching | Nov 25, 2022 | News | 0
Treatment involves adults with certain forms of advanced stomach and oesophageal cancer
Read Moreby John Pinching | Nov 11, 2022 | News | 0
Facility also includes a cell culture suite, quality control laboratories and technology labs
Read Moreby John Pinching | Jul 15, 2022 | News | 0
Armed forces veterans and people who were exposed to asbestos could benefit from the therapy
Read Moreby Lucy Parsons | Nov 8, 2021 | News | 0
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
Read Moreby Lucy Parsons | Aug 19, 2021 | News | 0
Option is a collaboration between BMS and AI-driven pharmatech Exscientia
Read Moreby Lucy Parsons | Aug 18, 2021 | News | 0
Phase III trial showed significant survival benefit over chemotherapy alone
Read Moreby Lucy Parsons | Aug 4, 2021 | News | 0
First treatment to be approved for UK MPM patients for more than 15 years
Read Moreby Lucy Parsons | Jun 30, 2021 | News | 0
Immunotherapy regimen approved to treat metastatic colorectal cancer after prior chemotherapy
Read Moreby Lucy Parsons | Jun 10, 2021 | News | 0
Opdivo plus chemotherapy or Yervoy demonstrated overall survival benefit in PD-L1-positive and all-randomised populations
Read Moreby Lucy Parsons | May 20, 2021 | News | 0
BMS will pay Agenus $200m upfront and up to $1.36bn in development, regulatory and commercial milestones
Read Moreby Lucy Parsons | May 14, 2021 | News | 0
Cost-effectiveness watchdog recommends first immunotherapy for unresectable advanced oesophageal cancer
Read Moreby Lucy Parsons | Apr 26, 2021 | News | 0
Deucravacitinib demonstrated superior skin clearance compared with Otezla
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479